BioCryst Pharmaceuticals announced that it has signed a licensing agreement with the Irish subsidiary of Neopharmed Gentili regarding the rights to the hereditary angioedema treatment drug Navenibart in Europe.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Chinese 3D vision AI startup Sensing4D AI submits IPO application to US stock market: plans to raise $35 million and advance embodied intelligence simulation.
Sensing4D AI plans to go public on Nasdaq, aiming to raise $35 million, with a primary focus on 3D reconstruction and embodied intelligence simulation. The company's annual revenue is $29 million.
UK S&P Global Composite PMI improves to 53.1 in October vs. 51.8 expected
Rezera (RZRA.US) submits IPO application: Oral NLRP3 inhibitor pipeline progresses, Phase 3 PAD trial scheduled to begin in 2027
Rezera plans to go public on Nasdaq to raise 100 millions USD. Its oral NLRP3 inhibitor will initiate a Phase III trial for PAD, with data expected in 2028.
Crypto prices
More
